Loading...
XNYSEHAB
Market cap382mUSD
Jan 10, Last price  
7.60USD
1D
-2.56%
1Q
5.56%
IPO
-66.58%
Name

Enhabit Inc

Chart & Performance

D1W1MN
XNYS:EHAB chart
P/E
P/S
0.37
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
1.05b
-3.40%
1,092,000,0001,078,200,0001,106,600,0001,083,100,0001,046,300,000
Net income
-81m
L
24,000,00075,000,000111,100,00062,500,000-80,500,000
CFO
48m
-39.58%
59,500,00024,900,000123,300,00080,100,00048,400,000
Earnings
Mar 04, 2025

Profile

Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company also offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. As of March 31, 2022, it operated in 252 home health agencies and 99 hospice agencies across 34 states. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was incorporated in 2014 and is headquartered in Dallas, Texas. As of July 1, 2022, Enhabit, Inc. operates as a standalone company.
IPO date
Jun 23, 2022
Employees
10,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
1,046,300
-3.40%
1,083,100
-2.12%
Cost of revenue
977,200
942,500
Unusual Expense (Income)
NOPBT
69,100
140,600
NOPBT Margin
6.60%
12.98%
Operating Taxes
(11,400)
28,900
Tax Rate
20.55%
NOPAT
80,500
111,700
Net income
(80,500)
-228.80%
62,500
-43.74%
Dividends
(654,900)
Dividend yield
99.33%
Proceeds from repurchase of equity
(595,100)
BB yield
90.26%
Debt
Debt current
46,100
37,100
Long-term debt
630,200
630,200
Deferred revenue
Other long-term liabilities
21,500
1,900
Net debt
648,900
644,400
Cash flow
Cash from operating activities
48,400
80,100
CAPEX
(3,500)
(7,100)
Cash from investing activities
(5,300)
(42,300)
Cash from financing activities
(40,500)
(18,600)
FCF
72,900
73,900
Balance
Cash
27,400
22,900
Long term investments
Excess cash
Stockholders' equity
286,500
471,400
Invested Capital
1,345,400
1,505,400
ROIC
5.65%
7.35%
ROCE
5.14%
9.08%
EV
Common stock shares outstanding
49,900
50,100
Price
10.35
-21.35%
13.16
 
Market cap
516,465
-21.67%
659,312
 
EV
1,197,365
1,337,412
EBITDA
100,000
174,200
EV/EBITDA
11.97
7.68
Interest
43,000
15,000
Interest/NOPBT
62.23%
10.67%